We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vermillion Announces Closing of Equity Financing
News

Vermillion Announces Closing of Equity Financing

Vermillion Announces Closing of Equity Financing
News

Vermillion Announces Closing of Equity Financing

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vermillion Announces Closing of Equity Financing"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vermillion, Inc. has announced that it has closed a previously announced private placement through which 8.0 million shares of the Company's common stock were purchased by Oracle Investment Management, Jack W. Schuler, Matthew W. Strobeck and other investors.

Gross proceeds of the private placement totaled approximately $13.2 million, with net proceeds totaling approximately $11.8 million after anticipated offering expenses. Emerging Growth Equities, Ltd. advised the company on this transaction.

As previously announced, Vermillion also issued warrants exercisable for 12.5 million shares of the Company's common stock at $1.46 per share as part of the close.

If and when the warrants are exercised, Vermillion will realize an additional $18.3 million in proceeds, bringing the total investment to $31.5 million before transaction costs.

Proceeds from this transaction will be used to increase test sales and improve reimbursement for OVA1, expand the commercial opportunity into new markets, and advance one or more next-generation ovarian cancer diagnostic tests.

Vermillion has also announced that its Board of Directors has approved an amendment to the Company's bylaws to increase the number of directors of the Company from six to eight persons, creating two new Class III director positions. This increase was required under the terms of the private placement.

Advertisement